Syndax Pharmaceuticals, Inc. (SNDX) is a Biotechnology company in the Healthcare sector, currently trading at $24.43. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is SNDX = $39 (+61% upside).
Valuation: SNDX trades at a trailing Price-to-Earnings (P/E) of -7.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Financials: revenue is $172M, +627.8%/yr average growth. Net income is $285M (loss), growing at -29.1%/yr. Net profit margin is -165.6% (negative). Gross margin is 96% (-0.5 pp trend).
Balance sheet: total debt is $346M against $65M equity (Debt-to-Equity (D/E) ratio 5.36, leveraged). Current ratio is 4.4 (strong liquidity). Debt-to-assets is 65.4%. Total assets: $530M.
Analyst outlook: 20 / 22 analysts rate SNDX as buy (91%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 66/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
